您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Salicylanilide(WR10019)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Salicylanilide(WR10019)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Salicylanilide(WR10019)图片
CAS NO:87-17-2
规格:≥98%
包装与价格:
包装价格(元)
500mg电议
1g电议
2g电议
5g电议
10g电议
100g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)213.23
FormulaC13H11NO2
CAS No.87-17-2
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 43 mg/mL (201.7 mM)
Water: <1 mg/mL
Ethanol: 18 mg/mL (84.4 mM)
Other info

Chemical Name: Benzamide, 2-hydroxy-N-phenyl-

InChi Key: WKEDVNSFRWHDNR-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H11NO2/c15-12-9-5-4-8-11(12)13(16)14-10-6-2-1-3-7-10/h1-9,15H,(H,14,16)

SMILES Code: O=C(NC1=CC=CC=C1)C2=CC=CC=C2O

Synonyms2-Hydroxybenzanilide; WR10019; WR-10019; WR 10019
实验参考方法
In Vitro

In vitro activity: Some salicylanilides and salicylamides could inhibit HIV virus by targeting of HIV-1 integrase or reverse transcriptase. Hepatitis C virus could be potentially afflicted by salicylanilides on the level of two enzymes – NS3 protease and NS5B RNA polymerase. Nitazoxanide is a nitrothiazole derivative of salicylamide useful for the treatment of protozoal and bacterial infections with an extended range of antiviral activity and innovative mechanism of action, especially against hepatitis and influenza viruses or rotaviruses. Nitazoxanide, its metabolite tizoxanide and their derivatives are a very promising stream in the development of new antiviral compounds. Salicylanilides is potential virulence inhibitors attributable to a blockade of the type III secretion pathway. Many salicylanilide ester derivatives have been demonstrated an effective and promising treatment against pathogenic fungi and bacteria (especially against Gram-positive, tuberculous and atypical mycobacterial strains), including strains such as methicillinresistant Staphylococcus aureus and isoniazid-resistant mycobacteria which are resistant to one or more clinically used drugs.

In Vivo
Animal model
Formulation & Dosage
References

Mini Rev Med Chem. 2011 Oct;11(11):956-67; Curr Pharm Des. 2011;17(32):3494-505.